CO2023017275A2 - Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno - Google Patents

Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno

Info

Publication number
CO2023017275A2
CO2023017275A2 CONC2023/0017275A CO2023017275A CO2023017275A2 CO 2023017275 A2 CO2023017275 A2 CO 2023017275A2 CO 2023017275 A CO2023017275 A CO 2023017275A CO 2023017275 A2 CO2023017275 A2 CO 2023017275A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
administration
anticancer agent
treating
preventing
Prior art date
Application number
CONC2023/0017275A
Other languages
English (en)
Spanish (es)
Inventor
Zhiwei Qiao
Manami Honda
Shouta Akimoto
Tomoki Sasaki
Noriko Kaji
Koichiro Fukuda
Tohru Mizushima
Ken-Ichiro Tanaka
Original Assignee
Ltt Bio Pharma Co Ltd
Musashino Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltt Bio Pharma Co Ltd, Musashino Univ filed Critical Ltt Bio Pharma Co Ltd
Publication of CO2023017275A2 publication Critical patent/CO2023017275A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2023/0017275A 2021-05-18 2023-12-14 Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno CO2023017275A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021083610 2021-05-18
PCT/JP2022/020473 WO2022244757A1 (ja) 2021-05-18 2022-05-17 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Publications (1)

Publication Number Publication Date
CO2023017275A2 true CO2023017275A2 (es) 2023-12-20

Family

ID=84141593

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0017275A CO2023017275A2 (es) 2021-05-18 2023-12-14 Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno

Country Status (11)

Country Link
US (1) US20240261375A1 (cg-RX-API-DMAC7.html)
EP (1) EP4353251A4 (cg-RX-API-DMAC7.html)
JP (1) JP7504367B2 (cg-RX-API-DMAC7.html)
KR (1) KR102843447B1 (cg-RX-API-DMAC7.html)
CN (1) CN117279657A (cg-RX-API-DMAC7.html)
AU (1) AU2022278242B2 (cg-RX-API-DMAC7.html)
CA (1) CA3220333A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017275A2 (cg-RX-API-DMAC7.html)
MX (1) MX428431B (cg-RX-API-DMAC7.html)
TW (1) TWI867299B (cg-RX-API-DMAC7.html)
WO (1) WO2022244757A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024411340A1 (en) 2023-12-26 2026-06-18 Ltt Bio-Pharma Co., Ltd. Prophylactic and therapeutic agent for diseases caused by type i allergic reaction induced by anticancer agent
WO2025178511A1 (ru) * 2024-02-21 2025-08-28 Евгений Владимирович ГРИГОРЬЕВ Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653670B2 (ja) * 1985-10-28 1994-07-20 日研フ−ド株式会社 化学療法剤の副作用低減化剤
JPH04135485A (ja) * 1990-09-28 1992-05-08 Seikagaku Kogyo Co Ltd 白金錯体及び抗腫瘍剤
JP3232542B2 (ja) 1993-01-08 2001-11-26 宇部興産株式会社 ヒトCu,Zn型スーパーオキシドジスムターゼ誘導体及びその製造法
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
US6221848B1 (en) * 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
JP2001002585A (ja) * 1999-06-22 2001-01-09 Ltt Kenkyusho:Kk レシチン化スーパーオキシドジスムターゼ含有抗線維化剤
JP3792487B2 (ja) 1999-06-24 2006-07-05 株式会社Lttバイオファーマ レシチン化スーパーオキシドジスムターゼ含有医薬組成物
EP1292324A2 (en) 2000-05-05 2003-03-19 Novo Nordisk A/S Critical illness neuropathy
JP2002080395A (ja) * 2000-08-31 2002-03-19 Ltt Institute Co Ltd 心筋傷害処置剤
WO2004065410A2 (en) 2003-01-21 2004-08-05 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use
KR101183856B1 (ko) * 2004-10-12 2012-09-19 가부시키가이샤 엘티티 바이오파마 레시틴화 수퍼옥사이드 디스뮤타아제 조성물 및 그 제조방법
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2006169128A (ja) 2004-12-13 2006-06-29 Ltt Bio-Pharma Co Ltd 熱傷治療剤
JP4867540B2 (ja) 2006-09-20 2012-02-01 日本精工株式会社 無段変速装置
CA2671668A1 (en) * 2006-12-19 2008-06-26 Ltt Bio-Pharma Co., Ltd. Therapeutic composition for interstitial pheumonia
JP5459827B2 (ja) 2009-03-13 2014-04-02 株式会社Lttバイオファーマ 慢性閉塞性肺疾患改善剤
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
BR112014016497B1 (pt) 2012-01-05 2021-02-23 Pledpharma Ab complexos de metal misturados, composição farmacêutica compreendendo os mesmos, métodos de produção e uso
JP6545926B2 (ja) * 2012-11-30 2019-07-17 株式会社ナノエッグ 手足症候群治療用組成物
KR20170036753A (ko) 2014-07-31 2017-04-03 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학요법 유도된 말초 신경병증 (cipn)의 예방 및/또는 치료를 위한 cxcr2 길항제의 용도
EP2985036A3 (en) 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. CYP2J2 antagonists in the treatment of pain
JP6851639B2 (ja) 2015-07-16 2021-03-31 ゾミクス バイオファーマ, インコーポレイテッド プラチナ薬剤の毒性の予防方法
JP6650612B2 (ja) 2015-10-06 2020-02-19 パナソニックIpマネジメント株式会社 照明制御装置及び照明システム

Also Published As

Publication number Publication date
AU2022278242B2 (en) 2024-11-14
MX2023013777A (es) 2023-12-04
CA3220333A1 (en) 2022-11-24
BR112023024140A2 (pt) 2024-02-06
KR102843447B1 (ko) 2025-08-06
EP4353251A1 (en) 2024-04-17
CN117279657A (zh) 2023-12-22
TWI867299B (zh) 2024-12-21
JPWO2022244757A1 (cg-RX-API-DMAC7.html) 2022-11-24
KR20240008844A (ko) 2024-01-19
JP7504367B2 (ja) 2024-06-24
AU2022278242A1 (en) 2023-11-30
WO2022244757A1 (ja) 2022-11-24
TW202313100A (zh) 2023-04-01
MX428431B (es) 2025-11-13
EP4353251A4 (en) 2025-05-14
US20240261375A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
AR071003A1 (es) Farmaco contra cancer de higado
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
BR112018076639A2 (pt) quimioterapias de combinação
MX2023013777A (es) Composicion farmaceutica para tratar o prevenir un trastorno relacionado con la administracion de un agente anticancerigeno.
CL2025001707A1 (es) Dispersión sólida de un inhibidor de her2.
BR112018072201A2 (pt) composição compreendendo o componente à base de naftoquinona como ingrediente ativo, para prevenir ou melhorar a fadiga, cachexia, dor, declínio cognitivo e redução de células estaminais hematopoiéticas que são efeitos colaterais relacionados as drogas para tratamento anticancerígino
BR112022007998A2 (pt) Novo composto e composição farmacêutica para prevenção ou tratamento de câncer que compreende os mesmos
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
MX2018015893A (es) Compuestos anti-cancer.
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
AR126552A1 (es) Composición farmacéutica para prevenir o tratar la esclerosis sistémica
CL2025001708A1 (es) Esquema de dosificación de una dispersión sólida de un inhibidor de her2
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
NI201900128A (es) Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta
BR112019006633A2 (pt) combinações farmacêuticas de inibidor de histona desacetilase e inibidor de proteassoma ou fármaco imunomodulador para o tratamento de câncer hematológico
CO2024009030A2 (es) Composición farmacéutica para prevenir o tratar cáncer de mama triple negativo